Aravanis, Christ; Evangelou, I.
June 1963
Angiology;Jun1963, Vol. 14 Issue 6, p325
Academic Journal
This report describes our experience with 75 patients given Panwarfin (warfarin sodium, Abbott Laboratories). Our findings are basically in complete agreement with the previously reported facts of others, only our experience with maintenance dosage differs. It was found that an initial dose of 50 mg and a subsequent one of 2.5 to 5.0 mg were sufficient for producing very satisfactory levels of hypoprothroinbinemia in 90 per cent of the patients. Very few �escape periods� from the therapeutic range were observed. Minor hemorrhagic phenomena occurred in only four patients without any serious consequences. Two deaths occurred during the treatment, the one probably related to anticoagulant treatment. No other toxic phenomena were noticed. Vitamin K1 was proved very efficient in counteracting prothrombin depression. No differences were found between the oral and the intravenous use concerning dosage, induction and level of hyporothrombinemia, recovery or toxicity. Our experience with Panwarfin in conjunction with the reports that have been published is that warfarin sodium is a rapidly effective anticoagulant, producing a smooth curve of hyporothrombinemia, presenting no toxic reactions and easily counteracted by vitamin K1. All of these properties make Panwarfin a nearly ideal anticoagulant.


Related Articles

  • Warfarin testing every 12 weeks? Elliott, William T. // Primary Care Reports;Jan2012 Pharmacology Watch, p1 

    The article reports on a study which suggested testing on warfarin, an anticoagulant, may be safely done in stable patients every 12 weeks instead of the usual four-week interval. According to the study, patients in the 12-week group had fewer dose changes and secondary outcomes such as major...

  • Warfarin testing every 12 weeks?  // Clinical Cardiology Alert;Jan2012 Pharmacology Watch, p1 

    The article reports a study on the effect of increasing warfarin dosing which concluded that assessment of warfarin dosing every 12 weeks seems to be safe and noninferior, although further study is recommended.

  • Predicting Dose Response. Davies, Kevin // Bio-IT World;Sep2007, Vol. 6 Issue 7, p6 

    The article stresses the difficulty of predicting the response by people on the dosage of drugs administered to them. It notes that the drug label of anti-coagulant warfarin, which is considered one of the most commonly prescribed drugs in the U.S., will be revised to note the value of genetic...

  • ANTICOAGULANT DOSING CONVERSIONS.  // Monthly Prescribing Reference;Fall2013, p62 

    The article offers information on dosing conversions in anticoagulants. It mentions the conversion from Dabigtran to Warfarin and also informs about the use of parentral anticoagulant after switching from dabigtran. It mentions that the administration of Warfarin is based on creatinine clearance...

  • A comparison of a low-dose warfarin induction regimen with the modified Fennerty regimen in... Gedge, Jennifer; Orme, Susie // Age & Ageing;Jan2000, Vol. 29 Issue 1, p31 

    Presents information on a study which compared a low-dose warfarin induction regimen with the Fennerty regimen to reduce over-anticoagulation among elderly inpatients. Uses of warfarin; Subjects and methods used in the study; Results and conclusion.

  • Treating Clotting Disorders: A Balance between Preventing Clots and Bleeding.  // Women's Health Advisor;Feb2013, Vol. 17 Issue 2, p3 

    The article focuses on positive and negative effect of anticoagulant drugs on human body. It informs about a study on warfarin, an anticoagulant drug that shows bleeding rates from the drug are higher than in clinical trials, and often are fatal depending on the amount of dose of drug that a...

  • Anticoagulation of older patients: a need to modify current practice. Loh, Pei Chong; Morgan, Kathy; Wynne, Hilary // Age & Ageing;Nov2000, Vol. 29 Issue 6, p551 

    Examines the practice of using anticoagulation drugs in older patients. Clinical practices regarding medication; Discussion on the need to modify the use of warfarin drug induction regimen; Results of a modified induction regimen among elderly patients.

  • The effect of warfarin on the pharmacokinetics and pharmacodynamics of napsagatran in healthy male volunteers. Faaij, R. A.; van Griensven, J. M. T.; Schoemaker, R. C.; Goggin, T.; Guenzi, A.; Kroon, J. M.; Burggraaf, J.; Cohen, A. F. // European Journal of Clinical Pharmacology;Apr2001, Vol. 57 Issue 1, p25 

    Objective: The effect of oral warfarin on the pharmacokinetics and pharmacodynamics of the synthetic direct thrombin inhibitor napsagatran was investigated. Methods: In an open, randomised, two-way crossover study, 12 healthy male volunteers were infused napsagatran (80 µg/min) for 48 h. Each...

  • Warfarin testing every 12 weeks?  // Clinical Oncology Alert;Jan2012 Supplement, p1 

    The article discusses a study which revealed that patients on a stable dose of warfarin for 6 months can be safely assessed for warfarin at 12-week intervals, instead of the recommended 4-week interval.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics